Abstract: Site-specific drug delivery to bone is considered to be achievable by utilizing acidic amino acid homopeptides. We found that fluorescence-labeled acidic amino acid (L-Asp or L-Glu) homopeptides containing six or more residues bound strongly to hydroxyapatite, which is a major component of bone, and were selectively delivered to and retained in bone after systemic administration. We explored the applicability of this result for drug delivery by conjugation of estradiol and levofloxacin with an L-Asp hexapeptide. We also similarly tagged an enzyme, tissue-nonspecific alkaline phosphatase, to see whether this would improve the efficacy of enzyme replacement therapy. The L-Asp hexapeptide-tagged drugs, including the enzyme, were selectively delivered to bone in comparison with the untagged drugs. It was expected that the ester linkage to the hexapeptide would be susceptible to hydrolysis in situ, releasing the drug or enzyme from the acidic oligopeptide. An in vivo experiment confirmed the efficacy of L-Asp hexapeptide-tagged estradiol and levofloxacin, although there was some loss of bioactivity of estradiol and levofloxacin in vitro, suggesting that the acidic hexapeptide was partly removed by hydrolysis in the body after delivery to bone. The adverse effect of estradiol on the uterus was greatly reduced by conjugation to the hexapeptide. These results support the usefulness of acidic oligopeptides as bone-targeting carriers for therapeutic agents. We present some pharmacokinetic and pharmacological properties of the L-Asp hexapeptide-tagged drugs and enzyme.
INTRODUCTION
Targeted delivery of biologically active agents to the site of action is a key concept in rational drug therapy to improve both the efficacy and the therapeutic index. Like other tissues, bone is susceptible to a range of diseases, but bone is unique in that it is, for the most part, composed of an inorganic compound, hydroxyapatite (HAP), which does not exist in soft tissues. Therefore, targeting a drug to HAP could be promising approach for selective drug delivery to bone.
We have proposed a novel drug delivery system to bone by using acidic oligopeptides. This unique approach is based on the physical properties of several bone noncollagenous proteins that have repetitive sequence of acidic amino acids (L-Asp or L-Glu) and bind to HAP [1] [2] [3] . Osteopontin and bone sialoprotein, two major noncollagenous proteins in bone, have L-Asp and L-Glu repetitive sequences, respectively, and rapidly bind to HAP after secretion in osteoblastic cell culture [4] [5] [6] . Thus, acidic oligopeptides are candidates as bone targeting carriers. To test this hypothesis, we synthesized homooligopeptides consisting of two to ten residues of acidic amino acids conjugated with 9-fluorenylmethylchloroformate (Fmoc), and eaxmined their affinity for HAP in vitro ( Table I) . The dissociation constant (K d ) value decreased with increasing number of acidic amino acid residues, and the maximal binding rate (B max ) was obtained at the length of six residues. The affinity for HAP was not related to optical isomeric form (L or D) or acidic amino acid species (Asp or Glu) [7] . In vivo, fluorescein-labeled L-Asp hexapeptide (FITC-D 6 ) rapidly disappeared from plasma (biological half-life: 60 minutes), and 95% of the administered FITC was excreted within 24 hours. However, FITC-D 6 was accumulated specifically in bone at 24 hours after systemic administration to mice, and was not detected in other tissues. Surprisingly, the FITC-D 6 was detectable in bone even at 14 days *Address Correspondence to this Author at the Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan; Tel: +81-76-265-2045; Fax: +81-76-234-4280; E-mail: miyaken@pharmacy.m.kanazawa-u.ac.jp after administration [8] . These results strongly support the potential usefulness of acidic oligopeptides as bone targeting carriers.
In this review, we describe the tagging of three model drugs, estradiol, levofloxacin (LVFX) and tissue-nonspecific alkaline phosphatase (TNSALP), with an acidic oligopeptide to examine the clinical feasibility of the acidic oligopeptide strategy for selective drug delivery to bone.
ESTRADIOL
Osteoporosis is a serious problem for postmenopausal and aged women, because estrogen deficiency plays a causative role in its development. Estrogen can act directly or indirectly on osteoblasts and osteoclasts through estrogen receptor-mediated mechanisms [9] [10] [11] [12] [13] , resulting in an anabolic effect on bone formation in estrogen-deficient animal models [14, 15] . Consequently, estrogen replacement therapy is an effective treatment in postmenopausal women to prevent reduction of the bone mineral density [16] . However, systemically administered estrogen is widely distributed to tissues other than bone, and prolonged therapy may increase the risks of endometritis, breast and endometrial cancer, and intrauterine hemorrhage [17, 18] . The development of osteoporosis therapies that are more efficient and selective to bone is therefore desirable to avoid such adverse reactions.
Estradiol was tagged with L-Asp hexapeptide at the 3 position (E 2 -3D 6 ) or the 17 position (E 2 -17 D 6 ) via succinate ester (Fig. 1) , and the pharmacokinetics and antiosteoporotic effects of these compounds were examined in ovariectomized (OVX) mice [7, 19] . First, the binding affinities of these compounds to human estrogen receptors, ER and ER , were tested in vitro. The affinities of E 2 -3D 6 and E 2 -17 D 6 to both estrogen receptors were about 100-fold and 10,000-fold, respectively, less than those of estradiol. However, it is unlikely that the tagged estradiols can permeate through the plasma membrane due to their hydrophilicity and large molecular size, and it seems probable that hydrolysis of the ester bond between estradiol and LAsp hexapeptide portion would be required for the tagged estradiols to show biological activity.
The bone concentration-time courses of estradiol, E 2 -3D 6 and E 2 -17 D 6 after a single intravenous injection (3.7 μmol/kg) were determined ( Fig. 2A) . At 6 hours after the injection, the tagged estradiols were distributed to bone at a 50-fold higher level than the untagged estradiol. Moreover, the levels of the tagged estradiols in bone decreased very slowly, falling to the endogenous level (10.5 3.3 pmol/g) by 7 days, whereas untagged estradiol declined to within the basal range within one day after the injection. The distribution of the tagged estradiols in the soft tissues tended to be lower than that of estradiol at 6 hours after the injection (Fig. 3) . In particular, untagged estradiol was most highly distributed to the uterus (where it might cause adverse effects such as endometritis) among the tissues exam- ined, while the accumulation of the tagged estradiols to the uterus was clearly lower than that of the untagged estradiol. The tagged estradiols appeared to be less efficiently taken up than estradiol into soft tissues, presumably because of their increased hydrophilicity due to the acidic peptide moiety. The distribution volume at the steadystate (Vd ss ) of the tagged estradiols was lower than that of the untagged estradiol (Table II) , supporting a reduced tissue distribution of E 2 -3D 6 and E 2 -17 D 6 .
It is well known that estradiol with a mono-or di-ester at position 3 or/and 17 shows prolonged estrogenic effects in the body due to the biological stability of esterified estradiol [20, 21] . This is because removal of the ester is necessary for further metabolism and excretion of estradiol, and the de-esterification step appears to be the ratelimiting process for the elimination of the esterified estradiol [22] . Indeed, at 6 hours after the injection of the untagged estradiol, the plasma concentration of estradiol had decreased almost to the endogenous level (7.6 ± 1.9 pmol/ml), whereas the tagged estradiols remained in the circulation at that time (E 2 -3D 6 ; 26.7 ± 9.0 pmol/ml, E 2 -17 D 6 , 22.0 ± 12.0 pmol/ml, respectively) (Fig. 2B) . The lower total body clearance (CL tot ) of the tagged estradiols, compared with that of the untagged estradiol, might be due to superior biological stability. This would be favorable for the long-term action of the tagged estradiols at bone.
To clarify the bone-selectivity of the tagged estradiols, OVX mice were treated with tagged (0.11, 0.37, or 1.1 μmol/kg, every seventh day) or untagged (0.37 μmol/kg, every third day) estradiol for 28 days. The tagged estradiols dose-dependently reversed the decreased bone mineral density (BMD) in the OVX mice, and the estrogenic effects were selective to bone, whereas the untagged estradiol increased not only the BMD, but also the uterine weight of the OVX mice (Fig. 4) . We confirmed that the tagged estradiols did not affect the liver, whereas estradiol caused liver hypertrophy and fatty degeneration, as seen histopathologically. These results suggest that the tagged estradiols reduce the risk of systemic adverse effects of estradiol, while retaining the osteogenic effect in bone.
There was little pharmacokinetic or biological difference between the two tagged estradiols in mice. The retention of E 2 -3D 6 in blood circulation and bone, and the anti-osteoporotic effect were larger than those of E 2 -17 D 6 . The difference may perhaps be due to greater stability of E 2 -3D 6 to hydrolysis in comparison with E 2 -17 D 6 , so that E 2 -3D 6 is retained for longer than E 2 -17 D 6 at the bone. We speculate that the tagged estradiols bound to bone are gradually hydrolyzed, possibly by peptidase, acid secreted from osteoclasts, and/or nonspecific esterase, on the bone surface, and then the released estradiol acts on estrogen receptors.
Thus, the acidic oligopeptide-tagged estradiols, E 2 -3D 6 and E 2 -17 D 6 , are promising candidates for treatment of postmenopausal osteoporosis. The prolonged effect and the selective delivery to bone should extend the medication interval and reduce the adverse effects of estradiol, resulting in improved quality of life for patients.
LEVOFLOXACIN
Osteomyelitis is a progressive infectious process resulting in inflammatory destruction of bone, bone necrosis and new bone formation. Chronic osteomyelitis is generally treated with surgical debrid Pharmacokinetic parameters were determined by means of model-independent moment analysis. Each value represents the mean ± S.D. of five mice. AUC0-6hours; the area under plasma concentration-time curve from 0 to 6 hours, MRT; the mean residence time, Vdss; the distribution volume at the steady-state, CLtot; the total body clearance. a , b Significantly different from estradiol at P < 0.01 and 0.05, respectively. Adapted from reference [7] and [19] .
Fig. (2). Time courses of femur (A) and plasma (B) concentration of estradiol, E2-3D6
, and E2-17 D6. Estradiol ( ), E2-3D6 ( ), or E2-17 D6 ( ) was administered to normal mice at a dose of 3.7 μmol/kg, and plasma and femur samples were obtained at the indicated time points. The remaining concentrations of estradiol, E2-3D6, and E2-17 D6 in the samples were determined with chemiluminescent immunoassay. Each point with bar represents the mean ± S.E. Adapted from reference [7] and [19] . Fig. (3) . Apparent tissue-to-plasma concentration ratios (Kp,app) of estradiol, E2-3D6, and E2-17 D6. Estradiol, E2-3D6, or E2-17 D6 was administered to normal mice at a dose of 3.7 μmol/kg, and the indicated tissues were obtained at 6 hours after the injection. The estradiol, E2-3D6, and E2-17 D6 concentrations in the tissues were determined with chemiluminescent immunoassay and divided by the plasma concentration. Each column with bar represents the mean ± S.E. Adapted from reference [7] and [19] .
ment following the administration of parenteral antibiotics, such aslactams or aminoglycosides. Without adequate debridment, most antibiotic regimens fail no matter what the duration of therapy. Even when all necrotic tissue is removed, the remaining bed of tissues must be considered as contaminated with the responsible pathogens. Therefore, it is recommended to treat the patient with antibiotics for at least 4 weeks [23] [24] [25] . Moreover, the serum bactericidal titer, which is defined as the maximal dilution of patient's serum able to kill the infecting organism in vitro, should be through 1 : 4 or greater for cure [26] . Thus, high dosage and long-term administration of antibiotics are required for the treatment of osteomyelitis, because delivery of antibiotics to bone is difficult. We chose fluoroquinolone, LVFX, as a parent drug to be tagged with acidic oligopeptide. Since the fluoroquinolones have a broad spectrum of activity in vitro, including activity against Gram negative organisms, Staphylococcus aureus (S. aureus), and S. epidermidis [27] [28] [29] , a means to improve their bone distribution should increase their therapeutic effectiveness.
LVFX was tagged with L-Asp hexapeptide at position 3 via glycolate ester (LVFX-D 6 , Fig. 1) . The minimum inhibitory concentration (MIC), as antimicrobial activity in vitro, of the LVFX-D 6 to S. aureus was 100-fold less than that of LVFX (LVFX, 0.35 nmol/ml; LVFX-D 6 44.3 nmol/ml). One reason for this may be the increased hydrophilicity arising from the acidic oligopeptide tag. Since fluoroquinolone acts by inhibiting bacterial topoisomerase II, which is responsible for the replication of double-stranded DNA, it must cross the bacterial membrane to be effective [30, 31] . A second possible reason is the modification of LVFX at the 3-carboxylate, because this group mediates binding to DNA topoisomerase II and transport across the bacterial membrane [32] . The marked reduction of the antimicrobial activity of the LVFX-D 6 indicates that release of LVFX from LVFX-D 6 by hydrolysis is required for biological activity, as in the cases of E 2 -3D 6 and E 2 -17 D 6 .
The bone-concentration and plasma-concentration time courses of LVFX-D 6 were determined in mice after an intravenous single injection (Fig. 5) . The level of LVFX-D 6 in bone was 100-fold higher than that of LVFX at two hours after the injection, and LVFX-D 6 was retained in bone at 100-fold higher concentration than LVFX after 7 days. Furthermore, LVFX generated by hydrolysis of the LVFX-D 6 was detectable in bone marrow and continued to be released for 7 days. In most soft tissues, except kidney and lung, LVFX-D 6 was distributed to a lesser extent than LVFX at two hours after the injection (Fig. 6) . It is known that LVFX shows extensive tissue penetration, and consequently can cause adverse effects in various tissues, including the cardiovascular system, central nervous system, skin, Fig. (4) . Effects of estradiol, E2-3D6, and E2-17 D6 on the femoral BMD (A) and uterine weight (B) of OVX mice. At 8 weeks after the OVX, subcutaneous injection was started with the indicated dose of estradiol (every third day), E2-3D6 (every seventh day), or E2-17 D6 (every seventh day) for 28 days. The femoral BMD was then determined with a dual x-ray absorptiometer (A), and the weight of the uterus was measured (B). Sham, sham-operated group; control, untreated control group. Each column with bar represents the mean ± S.D. *, **; significantly different from the control mice at p <0.05 and 0.01, respectively. Adapted from reference [7] and [19] . liver, musculoskeletal system, and kidney [33] [34] [35] . The reduced tissue distribution of LVFX-D 6 is consistent with that of the E 2 -3D 6 or E 2 -17 D 6 , and may be due to increased hydrophilicity. Unlike E 2 -3D 6 and E 2 -17 D 6 , LVFX-D 6 was distributed to kidney at a 3-fold higher level than LVFX at two hours after the injection, although at four hours the level was the same as that of LVFX in the LVFXadministered group. Since LVFX is known to be entirely excreted via the kidney [36] , the increased hydrophilicity of LVFX-D 6 may facilitate accumulation in kidney. The high kidney accumulation of LVFX-D 6 may also be partly due to the higher plasma concentration, resulting from the lower tissue distribution, at an early time after the injection. This accumulation of LVFX-D 6 in kidney, even though temporary, may increase the risk of adverse events, such as azotemia, nephropathy and interstitial nephritis, although the risk of adverse events involving other tissues may be decreased.
The therapeutic effect of LVFX-D 6 on osteomyelitis was evaluated using a murine model of osteomyelitis, prepared by inoculation of S. aureus into the tibia. The amount of S. aureus remaining in the tibia after a single intravenous injection of LVFX or LVFX-D 6 was determined and expressed in colony-forming units (CFU) (Fig. 7) . A slight reduction of the number of S. aureus was observed after the administration of both LVFX and LVFX-D 6 . The antimicrobial effect of LVFX, however, was temporary and the amount of S. aureus recovered to the level in the untreated control group at 6 days after the administration. On the other hand, LVFX-D 6 suppressed the growth of S. aureus for at least 6 days, showing a prolonged effect. However, the effect of the LVFX-D 6 was not sufficient to kill the inoculated S. aureus. This was presumably because an insufficient LVFX concentration was generated from LVFX-D 6 to kill S. aureus in bone. Indeed, over 10% of the initial concentration of LVFX-D 6 remained in bone even at 7 days after the injection, while E 2 -3D 6 and E 2 -17 D 6 were almost cleared after 7 days. Fluoroquinolones, including LVFX, show a concentration-dependent killing effect to susceptible organisms, and therefore higher concentrations of fluoroquinolones result in a more complete killing effect [37, 38] . Thus, the hydrolytic rate of the LVFX-D 6 appears to be an important determinant of the maximal antimicrobial effect.
In the case of LVFX-D 6 , rapid hydrolysis and consequent release of LVFX are especially important. However, it is still unknown what factor determines the half-life of acidic oligopeptide-tagged drugs in bone. For example, we tagged folic acid with L-Asp hexapeptide via an amide bond, which is highly resistant to hydrolysis in the body, for use in methotrexate-leukovorin therapy, since leucovorin, an active Fig. (6) . Apparent tissue-to-plasma concentration ratios (Kp,app) of LVFX and LVFX-D6. LVFX or LVFX-D6 was administered to normal mice at a dose of 27.7 μmol/kg, and the indicated tissues were obtained at two hours after the injection. The LVFX and LVFX-D6 concentrations of the tissues were determined with high-performance liquid chromatography and divided by the plasma concentration. Each column with bar represents the mean ± S.E. Fig. (7) . Antimicrobial effects of LVFX and LVFX-D6 on experimental murine osteomyelitis. S. aureus (10 5 CFU) was inoculated into mouse tibia, and 110.7 μmol/kg LVFX or LVFX-D6 was intravenously injected at 24 hours after the inoculation. The CFUs of the untreated control ( ), LVFX ( ), and LVFX-D6 ( ) groups were determined at the indicated time points. Each point with bar represents the mean ± S.E. *, **; significantly different from the control mice at p <0.05 and 0.01, respectively. form of folic acid, is well known to attenuate the toxicity of methotrexate [39] [40] [41] . The tagged folic acid was accumulated in bone and cleared very slowly, whereas folic acid was not detected in bone after systemic administration. Even at 21 days after the administration, 50% of the initial concentration of the tagged folic acid remained in bone. However, the tagged folic acid did not ameliorate methotrexate-induced myelosuppression at all, whereas folic acid did.
This finding emphasizes the importance of ensuring an appropriate susceptibility of an acidic oligopeptide-tagged drug to biological hydrolysis. To improve the effectiveness of LVFX-D 6 , further modification is required, such as devising a linkage susceptible to osteoclast-derived acid, or peptidase, or nonspecific esterase.
TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE
Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization caused by deficiency of TNSALP. Despite the presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals, clinical manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization that manifests as rickets in infants and children and osteomalacia in adults [42] . Osteoblasts modulate the composition of the bone matrix, where they deposit mineral in the form of HAP. Specialized buds from the osteoblasts' plasma membrane are called matrix vesicles (MVs). The initiation of matrix calcification by osteoblasts and chondrocytes appears to be mediated by release of MVs, which serve as a sheltered environment for HAP crystal formation [43] [44] [45] [46] . MVs are alkaline phosphatase-enriched, extracellular, membrane-invested bodies, inside which the first crystals of HAP bone mineral are generated. TNSALP hydrolyzes inorganic pyrophosphate (PP i ) to monophosphate (inorganic phosphate; P i ), which is important for growth of the HAP crystals [43, 44, [47] [48] [49] . Thus ALP functions as an inorganic pyrophosphatase [50, 51] . PP i itself impairs the growth of HAP crystals and acts as an inhibitor of mineralization [47, [52] [53] [54] . If TNSALP activity is insufficient, it fails to hydrolyze PP i and the resulting buildup of unhydrolyzed PP i in the perivesicular matrix inhibits the proliferation of pre-formed HAP crystals beyond the protective confines of MV membranes.
Since hypophosphatasia is caused by a deficiency of a single enzyme, TNSALP, this disorder is potentially amenable to enzyme replacement therapy (ERT). The results of ERT, however, with intravenous infusion of plasma ALP or purified liver ALP in patients with hypophosphatasia have been disappointing [55] [56] [57] [58] [59] . Recently, one report suggested that continuous delivery of a high dose of TNSALP to bone would be needed to induce physiological bone mineralization [60] . These observations suggested that these ALP enzymes administered intravenously were consumed mainly in visceral organs and not delivered to bone at physiologic levels capable of rescuing the lesions.
The cDNAs of three enzymes were prepared for further experiments: rhTNSALP (anchorless recombinant human TNSALP), CD 6 -TNSALP (anchorless human TNSALP tagged with a stretch of six LAsp residues at the C terminus), and CD 8 -TNSALP (anchorless human TNSALP tagged with a stretch of eight L-Asp residues at the C terminus) (Fig. 8) . We removed the glycosylphosphatidylinositol (GPI) anchoring signal peptide sequence from the C-terminus of the human TNSALP cDNA to allow secretion of the enzyme in the medium from Chinese hamster ovary (CHO-K1) cells. The resultant rhTNSALP was primarily secreted into the culture medium, as was also the case for CD 6 -to CD 8 -TNSALP cDNA, which also do not include the GPI anchoring signal peptide [61] . The presence of more than eight Asp residues caused a substantial reduction of the enzyme activity secreted into culture medium during the transient expression. Therefore, the CD 6 -and CD 8 -TNSALP enzymes were used for further experiments.
After purification of the three enzymes from the secretion media of stably transfected CHO-K1 cells, the enzymatic properties were determined. There was no significant difference in specific activity, Michaelis constant, or k cat among the three enymes. It is unnecessary to remove the L-Asp hexapeptide or octapeptide from the tagged enzymes as long as they retain enzymatic activity, since TNSALP physiologically acts extracellularly to degrade PP i . Therefore, the tagged enzymes themselves should be able to restore mineralization in hypophosphatasia patients. Indeed, in cultures of hypophosphatasia patient-derived bone marrow cells, we found that addition of one of the tagged enzymes resulted in a marked recovery of mineralization, like that seen with the untagged enzyme (Fig. 9) . This result indicates that, like TNSALP itself, the tagged enzyme can play a biological role in the mineralization process in vitro by providing free P i via the hydrolysis of -glycerophosphate. We added PP i , an inhibitor of mineralization, to see whether the TNSALP enzymes hydrolyze PP i to restore the mineralization. In the absence of added TNSALP, PP i itself completely inhibited the mineralization even in the presence of P i . The addition of the tagged enzymes restored the mineralization level to that of the PP i -free control culture, as did addition of TNSALP. Taken together, these results suggested that the tagged and untagged enzymes show similar bioactivity on mineralization by degrading PP i .
We then characterized the pharmacokinetic properties of the tagged enzymes. To evaluate the pharmacokinetic tissue distribution of the enzymes, fluorescence-labeled enzymes were prepared with Alexa dye. Each tagged enzyme showed a two-to four-fold increase in bone retention compared with the untagged enzyme for at least 7 days after intravenous injection. The distribution to other tissues was not significantly different among the three enzymes, while the halflives in the circulation were slightly different (rhTNSALP, 19.1 Fig. 9 . In vitro mineralization experiment with rhTNSALP, CD6-TNSALP, and CD8-TNSALP enzymes. Bone marrow cells from a hypophophatasia patient were seeded in 12-well plates at a density of 10,000 cell/cm 2 , and differentiated in the presence of 2.5 mM Pi or 2.5 mM -glycerophosphate as a phosphate source. The effect of each TNSALP enzyme on mineralization was evaluated in the presence of 50 μM PPi. Calcium deposits were visualized 12 days after the initiation of differentiation of bone marrow cells (A). The areas of nodules of calcium deposits from five fields of light-microscopic images were quantitated (B). *, **; significantly different from the PPi-treated control at p < 0.05 and 0.01, respectively. Adapted from reference [61] .
hours; CD 6 -TNSALP, 14.4 hours; CD 8 -TNSALP, 13.5 hours) after a single intravenous injection. The difference of half-lives in the circulation was possibly related to the carbohydrate structure, because the tagged enzymes were less sialylated than the untagged enzyme, based upon the result of lectin affinity chromatography [61] . It is known that a larger sialic acid residue content at the terminus of the carbohydrate chain contributes to a longer half-life of ALP in the blood circulation [62] [63] [64] .
These results demonstrate that the bone-targeting system with an acidic oligopeptide is also applicable to a large molecule, such as an enzyme, and suggest the possible clinical application of ERT for hypophosphatasia. Further studies are needed to confirm that these tagged enzymes are physiologically functional in vivo. The established hypophosphatasia mouse model [65, 66] should prove useful to evaluate the clinical effectiveness of ERT through the use of tagged and untagged recombinant enzymes.
CONCLUSION
The cumulative results of studies on acidic oligopeptide conjugation powerfully demonstrate the potential value of selective bone targeting of therapeutic drugs. Since the affinity of acidic oligopeptides for HAP appears to be strong, the targeting system should be widely applicable for small to large molecules. We have had successful results in bone targeting through acidic oligopeptide tagging, although the strong affinity of the acidic oligopeptide to HAP sometimes leads to difficulty in release of the parent drug, as was observed in the case of LVFX-D 6 . Controlled release of the parent molecule from the tagged molecule in bone should be a useful approach.
The acidic oligopeptide tagging altered the pharmacokinetic and biological properties, including the blood clearance, distribution to visceral organs, and biological activity, not only for small molecules, but also for a large molecule. The increased hydrophilicity owing to tagging is thought to be responsible for these alterations. In considering the clinical use of tagged molecules, it is likely that tagged molecules would not be suitable for oral administration because of their high hydrophilicity, and their susceptibility to peptidase and esterase in the gastrointestinal tract. Indeed, the bioavailability of E 2 -17 D 6 after oral administration was less than 10%. Therefore, we have suggested an alternative route, intranasal administration, to increase the bioavailability of tagged molecules. The bioavailability of E 2 -17 D 6 after intranasal administration was increased to 75% when the formulation was changed by incorporating 2,6-di-O-methyl--cyclodextrin, with which E 2 -17 D 6 formed an inclusion compound that could achieve prolonged residence in the nasal cavity [67] [68] [69] [70] . These results support the potential clinical usefulness of acidic oligopeptide-tagged drugs.
ERT is an established strategy for treating lysosomal storage diseases and is clinically available or in clinical trials for Gaucher disease, Fabry disease, Pompe disease, MPS I, MPS II, and MPS VI [71] [72] [73] [74] . Those ERTs result in marked improvement in the visceral organs, but little improvement in the bone or brain, since the enzymes are not delivered effectively to those tissues. Thus, lysosomal storage diseases would be a good candidate for bone targeting of therapeutic drugs using acidic oligopeptides, although further studies are needed to confirm the physiological efficacy of acidic oligopeptide-tagged enzyme. Many other potential applications of this unique bonetargeting system for drugs used to treat bone diseases can be envisaged, and the ability to achieve selective delivery to bone could make other drugs suitable as candidates too. 
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